InflaRx

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell InflaRx and other ETFs, options, and stocks.

About IFRX

InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. Its primary product candidate is Vilobelimab. 

CEO
Niels Christoph Riedemann
CEONiels Christoph Riedemann
Employees
74
Employees74
Headquarters
Jena, Thueringen
HeadquartersJena, Thueringen
Founded
2007
Founded2007
Employees
74
Employees74

IFRX Key Statistics

Market cap
57.15M
Market cap57.15M
Price-Earnings ratio
-0.78
Price-Earnings ratio-0.78
Dividend yield
Dividend yield
Average volume
548.55K
Average volume548.55K
High today
$0.8929
High today$0.8929
Low today
$0.80
Low today$0.80
Open price
$0.8652
Open price$0.8652
Volume
405.97K
Volume405.97K
52 Week high
$2.82
52 Week high$2.82
52 Week low
$0.7113
52 Week low$0.7113

IFRX News

TipRanks 1d
InflaRx Receives Nasdaq Deficiency Notice for Share Price

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to...

Simply Wall St 6d
Is InflaRx In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, although softwar...

Is InflaRx In A Good Position To Deliver On Growth Plans?

Analyst ratings

86%

of 7 ratings
Buy
85.7%
Hold
14.3%
Sell
0%

People also own

Based on the portfolios of people who own IFRX. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.